Online citations, reference lists, and bibliographies.
← Back to Search

Transscleral Drug Delivery To Retina And Posterior Segment Disease

Ann-Marie Ako-Adounvo, P. Karla
Published 2018 · Medicine

Cite This
Download PDF
Analyze on Scholarcy
Share
The complexities of the anatomical and physiological barriers pose a challenge for the treatment of posterior segment eye disease. Ineffective delivery of the drug to the posterior site is regarded a major contributing factor for treatment failure. Transscleral drug delivery aims the large surface area of the sclera for increased drug absorption when compared to the intravitreal injections. This chapter addresses posterior segment diseases, treatment approaches and routes of drug administration, with emphasis on transscleral drug delivery. Application of novel strategies such as iontophoresis have been useful for improved permeability and drug delivery of ionized drugs. Further, newer techniques such as, polymeric colloids, implants, and thermoresponsive gels are currently investigated for efficiency.
This paper references
10.1016/J.ADDR.2005.09.004
Topical and systemic drug delivery to the posterior segments.
Patrick M Hughes (2005)
Peroxidase diffusion in the normal and laser-coagulated primate retina.
G. Peyman (1972)
10.4103/0976-500X.120947
Anti-vascular endothelial growth factor drugs safety and efficacy in ophthalmic diseases
Pasquale Ventrice (2013)
10.2174/1877912311202020126
Advances in Ocular Iontophoresis Research
Pradeep K. Karla and Ann-Marie Ako-Adounvo (2012)
Human scleral permeability. Effects of age, cryotherapy, transscleral diode laser, and surgical thinning.
T. Olsen (1995)
10.1124/dmd.110.037408
Influence of Drug Solubility and Lipophilicity on Transscleral Retinal Delivery of Six Corticosteroids
A. Thakur (2011)
10.1159/000108117
Transport Barriers in Transscleral Drug Delivery for Retinal Diseases
S. Kim (2007)
10.1016/j.neuron.2012.06.018
Mechanisms of Age-Related Macular Degeneration
J. Ambati (2012)
10.1517/17425247.4.4.371
Novel approaches to retinal drug delivery
Kumar G. Janoria (2007)
10.1016/0014-4835(84)90053-8
Characterization of collagen from normal human sclera.
F. Keeley (1984)
10.1080/07853890600946724
Age‐related macular degeneration—emerging pathogenetic and therapeutic concepts
K. Gehrs (2006)
Diffusion of high molecular weight compounds through sclera.
J. Ambati (2000)
10.1093/OXFORDJOURNALS.QJMED.A067145
The natural history of diabetic retinopathy.
A. G. Burditt (1968)
10.1016/J.AJO.2004.05.028
Vitreous concentrations of triamcinolone acetonide in human eyes after intravitreal or subtenon injection.
M. Inoue (2004)
10.2147/OPTH.S118409
Systemic side effects of eye drops: a pharmacokinetic perspective
A. Farkouh (2016)
10.1111/j.1442-9071.2010.02363.x
Anatomy and physiology of the human eye: effects of mucopolysaccharidoses disease on structure and function – a review
C. Willoughby (2010)
10.1016/S0002-9394(99)80096-8
Human sclera: thickness and surface area.
T. Olsen (1998)
10.1016/S0169-409X(01)00192-2
Biodegradable scleral plugs for vitreoretinal drug delivery.
T. Yasukawa (2001)
10.1517/17425247.1.1.99
Periocular routes for retinal drug delivery
Swita Raghava (2004)
10.1001/ARCHOPHT.122.4.564
Prevalence of age-related macular degeneration in the United States.
P. D. Jong (2004)
10.4172/2167-7956.1000116
Nanoparticulate Transscleral Ocular Drug Delivery
Jigar Shah (2014)
10.1167/iovs.07-0214
Effect of eye pigmentation on transscleral drug delivery.
N. Cheruvu (2008)
10.1136/bjophthalmol-2012-301917
Evaluation of choroidal thickness in retinitis pigmentosa using enhanced depth imaging optical coherence tomography
D. Dhoot (2012)
10.1007/BF00146764
The blood-retinal barriers
J. Cunha-vaz (2004)
10.1007/978-1-4419-9920-7_7
Transscleral Drug Delivery
D. Geroski (2011)
10.1016/J.SURVOPHTHAL.2006.02.006
A review of anterior segment dysgeneses.
F. Idrees (2006)
10.1001/ARCHOPHT.122.7.1019
Racial variations in causes of vision loss in nursing homes: The Salisbury Eye Evaluation in Nursing Home Groups (SEEING) Study.
D. S. Friedman (2004)
10.1007/s11095-007-9408-z
Drug Elimination Kinetics Following Subconjunctival Injection Using Dynamic Contrast-Enhanced Magnetic Resonance Imaging
S. Kim (2007)
10.1016/S0161-6420(02)01146-6
Ten-year incidence and progression of age-related maculopathy: The Beaver Dam eye study.
R. Klein (2002)
10.1016/S1569-2590(05)10012-3
Drug Delivery to the Eye
A. Mitra (2005)
10.1016/j.preteyeres.2008.10.001
Molecular pathology of age-related macular degeneration
X. Ding (2009)
10.2147/OPTH.S6700
Optimal management of cytomegalovirus retinitis in patients with AIDS
M. Stewart (2010)
10.1007/978-3-319-25498-2_3
Drug Transport Across Blood-Ocular Barriers and Pharmacokinetics
J. Cunha-Vaz (2016)
10.1016/S0014-4835(03)00213-6
The blood-retinal barriers system. Basic concepts and clinical evaluation.
J. Cunha-vaz (2004)
10.1016/j.ijpharm.2017.07.065
Non-invasive strategies for targeting the posterior segment of eye.
Asadullah Madni (2017)
10.1016/J.JCONREL.2005.09.049
Iontophoresis: a non-invasive ocular drug delivery.
E. Eljarrat-Binstock (2006)
10.1097/01.iae.0000242842.14624.e7
DEVELOPMENT OF RANIBIZUMAB, AN ANTI–VASCULAR ENDOTHELIAL GROWTH FACTOR ANTIGEN BINDING FRAGMENT, AS THERAPY FOR NEOVASCULAR AGE-RELATED MACULAR DEGENERATION
N. Ferrara (2006)
10.1155/2013/343560
Pathophysiology of Diabetic Retinopathy
J. Tarr (2013)
10.1097/00006982-199313030-00016
Risk of developing cytomegalovirus retinitis in persons infected with the human immunodeficiency virus.
P. Pertel (1992)
10.1056/NEJMOA042760
Pegaptanib for neovascular age-related macular degeneration.
E. Gragoudas (2004)
10.1016/S2214-109X(17)30293-0
Magnitude, temporal trends, and projections of the global prevalence of blindness and distance and near vision impairment: a systematic review and meta-analysis.
R. Bourne (2017)
10.1006/RTPH.1998.1243
Binding of drugs to eye melanin is not predictive of ocular toxicity.
B. Leblanc (1998)
10.1016/j.drudis.2010.12.004
Drug delivery to the posterior segment of the eye.
T. R. Thrimawithana (2011)
10.1093/INFDIS/166.6.1223
Incidence and natural history of cytomegalovirus disease in patients with advanced human immunodeficiency virus disease treated with zidovudine. The Zidovudine Epidemiology Study Group.
J. Gallant (1992)
10.1016/S0896-1549(01)00009-8
Mechanism of age related macular degeneration
D. Husain (2002)
Drug delivery for posterior segment eye disease.
D. Geroski (2000)
10.1016/J.EXER.2005.08.007
A rabbit model for assessing the ocular barriers to the transscleral delivery of triamcinolone acetonide.
M. Robinson (2006)
10.1016/j.jconrel.2010.08.028
Barrier analysis of periocular drug delivery to the posterior segment.
V. Ranta (2010)
Topical drug delivery for posterior segment disease: Novel formulations offer possibilities for efficacious therapies through topical routes
Daniel F. Kiernan (2010)
10.1089/108076801753162807
Review: practical issues in intravitreal drug delivery.
D. Maurice (2001)
10.1089/108076804773710830
Scleral permeability of a small, single-stranded oligonucleotide.
R. Shuler (2004)
10.1021/JS9802594
Permeability of cornea, sclera, and conjunctiva: a literature analysis for drug delivery to the eye.
M. Prausnitz (1998)
10.1007/s11095-008-9694-0
Recent Perspectives in Ocular Drug Delivery
Ripal Gaudana (2008)
Ocular pharmacokinetics of dacarbazine following subconjunctival versus intravenous administration in the rabbit.
G. S. Kalsi (1991)
10.1016/j.drudis.2007.11.002
Current and future ophthalmic drug delivery systems. A shift to the posterior segment.
Eva M. del Amo (2008)
10.1167/iovs.07-1660
Human transscleral albumin permeability and the effect of topographical location and donor age.
O. A. Anderson (2008)
10.1211/jpp.59.5.0002
Cyclodextrin microparticles for drug delivery to the posterior segment of the eye: aqueous dexamethasone eye drops
T. Loftsson (2007)
10.1016/S0039-6257(00)00140-5
The role of oxidative stress in the pathogenesis of age-related macular degeneration.
S. Beatty (2000)
10.1007/978-3-319-47691-9_2
Anatomy of the Eye and Common Diseases Affecting the Eye
E. Addo (2016)
10.1167/IOVS.04-1051
Permeability of retinal pigment epithelium: effects of permeant molecular weight and lipophilicity.
L. Pitkänen (2005)
10.1124/DMD.30.4.421
Distribution of brimonidine into anterior and posterior tissues of monkey, rabbit, and rat eyes.
A. Acheampong (2002)
10.1016/S0002-9394(14)70778-0
Foscarnet-Ganciclovir Cytomegalovirus Retinitis Trial: 5. Clinical features of cytomegalovirus retinitis at diagnosis. Studies of ocular complications of AIDS Research Group in collaboration with the AIDS Clinical Trials Group.
A. Gilpin (1997)
10.1586/eop.09.70
Drug delivery to the posterior segment of the eye for pharmacologic therapy
Shalin S Shah (2010)
10.1201/B12950-10
Barriers to Transscleral Drug Delivery to the Retina
A. Almazan (2012)
10.1016/j.ajo.2011.02.009
Periocular triamcinolone acetonide injections for cystoid macular edema complicating noninfectious uveitis.
H. Leder (2011)
Route of absorption of drug and ointment after application to the eye.
J. Scruggs (1978)
10.1089/JOP.1986.2.67
Topical ocular drug delivery: recent developments and future challenges.
V. Lee (1986)
10.1167/iovs.10-5392
Ophthalmic drug delivery systems for the treatment of retinal diseases: basic research to clinical applications.
H. Edelhauser (2010)
10.1089/108076804772745419
Effects of dorzolamide hydrochloride on ocular tissues.
J. Inoue (2004)
10.1167/IOVS.06-0954
Pharmacokinetics of intraocular drug delivery by periocular injections using ocular fluorophotometry.
D. Ghate (2007)
10.1517/17425247.3.2.275
Ocular drug delivery
D. Ghate (2006)
10.1089/jop.2007.0117
Pharmacokinetic study of dexamethasone disodium phosphate using intravitreal, subconjunctival, and intravenous delivery routes in rabbits.
K. Hosseini (2008)
10.1016/J.OPHTHA.2007.03.008
The natural history and prognosis of neovascular age-related macular degeneration: a systematic review of the literature and meta-analysis.
T. Wong (2008)
10.1167/IOVS.02-0791
Subconjunctival nano- and microparticles sustain retinal delivery of budesonide, a corticosteroid capable of inhibiting VEGF expression.
U. Kompella (2003)
10.1016/j.ophtha.2012.09.006
Intravitreal aflibercept (VEGF trap-eye) in wet age-related macular degeneration.
J. Heier (2012)
drug delivery to the Posterior segment: an update
D. Boyer (2013)
10.7326/0003-4819-109-12-963
The diagnosis of cytomegalovirus retinitis.
J. N. Bloom (1988)
10.1016/S0161-6420(95)30953-0
Histopathology of bone spicule pigmentation in retinitis pigmentosa.
Z. Li (1995)
10.1111/J.1600-0420.2007.00885.X
Topical and systemic absorption in delivery of dexamethasone to the anterior and posterior segments of the eye.
H. Sigurdsson (2007)
10.1016/j.jconrel.2014.05.031
Nanotherapy for posterior eye diseases.
I. P. Kaur (2014)



Semantic Scholar Logo Some data provided by SemanticScholar